Live Breaking News & Updates on Shankar musunuri

Stay informed with the latest breaking news from Shankar musunuri on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Shankar musunuri and stay connected to the pulse of your community

OCUGEN ANNOUNCES POSITIVE CLINICAL STUDY UPDATE FROM THE PHASE 1/2 TRIAL OF OCU400, A MODIFIER GENE THERAPY PRODUCT CANDIDATE, FOR THE TREATMENT OF RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS

MALVERN - Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced a clinical study...

Los-angeles , California , United-states , Arun-upadhyay , Lejla-vajzovic , David-boyer , Shankar-musunuri , Duke-vitreoretinal-fellowship-program , Duke-eye-center , Retina-vitreous-associates-medical-group , Keck-school-of-medicine-los-angeles , Head-of-research

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Shankar-musunuri , Lejla-vajzovic , Arun-upadhyay , Duke-university-school-of-medicine , Ocugen-inc , University-of-miami , Head-of-clinical-development , Linkedin , Head-of-communications , Head-of-research , Bascom-palmer-eye-institute

Ocugen to Host Virtual Investor & Analyst Event on

Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis...

Lejla-vajzovic , Arun-upadhyay , Shankar-musunuri , Ocugen-inc , Exchange-commission , University-of-miami , Twitter , Head-of-communications , Head-of-research , Linkedin , Duke-university-school-of-medicine

Ocugen (OCGN) Reports Positive Clinical Study Update from the Phase 1/2 Trial of OCU400

Ocugen (OCGN) Reports Positive Clinical Study Update from the Phase 1/2 Trial of OCU400
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Los-angeles , California , United-states , Shankar-musunuri , Lejla-vajzovic , Arun-upadhyay , David-boyer , Head-of-research , Aboutocugen-inc-ocugen , Linkedin , Twitter , Keck-school-of-medicine-los-angeles

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity ...

Los-angeles , California , United-states , Arun-upadhyay , David-boyer , Lejla-vajzovic , Shankar-musunuri , Retina-vitreous-associates-medical-group , Ocugen-inc , Retina-foundation-of-the , Duke-university-school-of-medicine , Aboutocugen-inc

Form 8-K Ocugen, Inc. For: Sep 13

Form 8-K Ocugen, Inc. For: Sep 13
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Washington , United-states , Delaware , Pennsylvania , Malvern , Shankar-musunuri , Securities-exchange , Nasdaq-stock-market , Securities-exchange-act , Earliest-event-reported , Exact-name , Former-name

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier ...

FavorablesafetyandtolerabilityprofileofOCU400investigationaldrugproductin RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity (BCVA) and Multi-Luminance Mobility Testing (MLMT), as well as positive trends in Low-Luminance

Los-angeles , California , United-states , Arun-upadhyay , Lejla-vajzovic , David-boyer , Shankar-musunuri , Head-of-research , Ocugen-inc , Retina-vitreous-associates-medical-group , Linkedin , Head-of-communications

Ocugen, Inc. (NASDAQ:OCGN) Q2 2023 Earnings Call Transcript

Ocugen, Inc. (NASDAQ:OCGN) Q2 2023 Earnings Call Transcript August 22, 2023 Operator: Good morning and welcome to Ocugen’s second quarter 2023 financial results and business update. Please note that this call is being recorded at this time. All participants’ lines are in listen-only mode. Following the speakers’ commentary, there will be a question and answer […]

Shankar-musunuri , Jennifer-kim , William-ramakanth , Swayampakula-ramakanth , Arun-upadhyay , Robert-leboyer , Daniil-gataulin , Pressmaster-shutterstock , Cantor-fitzgerald , A-nuclear , Exchange-commission

Ocugen Provides Business Update with Second Quarter 2023 Financial Results

Ocugen Provides Business Update with Second Quarter 2023 Financial Results
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Shankar-musunuri , Head-of-communications , Ocugen-inc , Exchange-commission , Twitter , Association-for-research , Linkedin , Conference-call , Webcast-tomorrow , Investigational-new-drug , Applications-cleared

Ocugen (OCGN) Q2 2023 Earnings Call Transcript

OCGN earnings call for the period ending June 30, 2023.

Chad , Jen-kim-cantor-fitzgerald , Jennifer-kim , Daniil-gataulin-chardan , William-ramakanth , Arun-upadhyay , Shankar-musunuri , Daniil-gataulin , A-nuclear , Shankar-musunuri-co , Association-for-research , Tiffany-hamilton-head-of-corporate-communications